CymaBay Therapeutics Inc (NASDAQ:CBAY)
| 14.73 BATS BZX Real-Time Price As of 11:23am ET |  +0.125 / +0.86%Today’s Change | 3.16 Today|||52-Week Range 18.20 | +134.93% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.8B |
Company Description
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Contact Information
CymaBay Therapeutics, Inc. 7575 Gateway Boulevard Newark California 94560 |
Employees
Shareholders
| Other institutional | 51.99% |
| Mutual fund holders | 26.60% |
| Individual stakeholders | 11.15% |
Top Executives
| Sujal Shah | President, Chief Executive Officer & Director |
| Harish Shantharam | Chief Financial Officer |
| Charles A. McWherter | President-Research & Development |
| Paul T. Quinlan | Secretary & Chief Compliance Officer |
| Patrick J. O'Mara | Senior Vice President-Business Development |
